OMEROS CORP Share-based Payment Arrangement, Expense
OMEROS CORP (OMER) reported Share-based Payment Arrangement, Expense of $1.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-12
- OMEROS CORP share-based payment arrangement, expense for the quarter ending 2026-06-30 was $1.62M, a 21.50% decline year-over-year.
- OMEROS CORP share-based payment arrangement, expense for the quarter ending 2026-03-31 was $1.89M, a 22.99% decline year-over-year.
- OMEROS CORP share-based payment arrangement, expense for the quarter ending 2025-06-30 was $2.06M, a 25.40% decline year-over-year.
- OMEROS CORP share-based payment arrangement, expense for the quarter ending 2025-03-31 was $2.45M, a 7.71% decline year-over-year.
- OMEROS CORP share-based payment arrangement, expense for fiscal 2025 was $8.19M, a 21.93% decline from fiscal 2024.
- OMEROS CORP share-based payment arrangement, expense for fiscal 2024 was $10.49M, a 9.93% decline from fiscal 2023.
- OMEROS CORP share-based payment arrangement, expense for fiscal 2023 was $11.65M, a 17.21% decline from fiscal 2022.
- OMEROS CORP share-based payment arrangement, expense for fiscal 2022 was $14.07M, a 20.18% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.62M 10-Q · filed 2026-08-12 | $3.51M 10-Q · filed 2026-08-12 | ||
| 2026-03-31 | $1.89M 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $8.19M 10-K · filed 2026-03-31 | |||
| 2025-06-30 | $2.06M 10-Q · filed 2026-08-12 | $4.52M 10-Q · filed 2026-08-12 | $6.94M derived: sum of 3 quarters · filed 2026-08-12 | $9.59M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.45M 10-Q · filed 2026-05-13 | $4.88M derived: sum of 2 quarters · filed 2026-05-13 | $7.52M derived: sum of 3 quarters · filed 2026-05-13 | $10.29M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $5.07M derived: sum of 2 quarters · filed 2026-03-31 | $7.83M derived: sum of 3 quarters · filed 2026-03-31 | $10.49M 10-K · filed 2026-03-31 |
| 2024-09-30 | $2.64M 10-Q · filed 2024-11-13 | $5.41M derived: sum of 2 quarters · filed 2024-11-13 | $8.07M 10-Q · filed 2024-11-13 | $10.76M derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-06-30 | $2.77M 10-Q · filed 2024-08-07 | $5.43M 10-Q · filed 2024-08-07 | $8.12M derived: sum of 3 quarters · filed 2026-03-31 | $11.35M derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-03-31 | $2.66M 10-Q · filed 2024-05-15 | $5.35M derived: sum of 2 quarters · filed 2026-03-31 | $8.58M derived: sum of 3 quarters · filed 2026-03-31 | $11.36M derived: sum of 4 quarters · filed 2026-03-31 |
| 2023-12-31 | $2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $5.93M derived: sum of 2 quarters · filed 2026-03-31 | $8.70M derived: sum of 3 quarters · filed 2026-03-31 | $11.65M 10-K · filed 2026-03-31 |
| 2023-09-30 | $3.23M 10-Q · filed 2024-11-13 | $6.01M derived: sum of 2 quarters · filed 2024-11-13 | $8.96M 10-Q · filed 2024-11-13 | $12.22M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-06-30 | $2.77M 10-Q · filed 2024-08-07 | $5.72M 10-Q · filed 2024-08-07 | $8.99M derived: sum of 3 quarters · filed 2025-03-31 | $12.83M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-03-31 | $2.95M 10-Q · filed 2024-05-15 | $6.22M derived: sum of 2 quarters · filed 2025-03-31 | $10.06M derived: sum of 3 quarters · filed 2025-03-31 | $13.13M derived: sum of 4 quarters · filed 2025-03-31 |
| 2022-12-31 | $3.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $7.11M derived: sum of 2 quarters · filed 2025-03-31 | $10.18M derived: sum of 3 quarters · filed 2025-03-31 | $14.07M 10-K · filed 2025-03-31 |
| 2022-09-30 | $3.84M 10-Q · filed 2023-11-09 | $6.92M derived: sum of 2 quarters · filed 2023-11-09 | $10.81M 10-Q · filed 2023-11-09 | $16.36M derived: sum of 4 quarters · filed 2024-04-01 |
| 2022-06-30 | $3.07M 10-Q · filed 2023-08-09 | $6.96M 10-Q · filed 2023-08-09 | $12.51M derived: sum of 3 quarters · filed 2024-04-01 | $18.21M derived: sum of 4 quarters · filed 2024-04-01 |
| 2022-03-31 | $3.89M 10-Q · filed 2023-05-09 | $9.44M derived: sum of 2 quarters · filed 2024-04-01 | $15.13M derived: sum of 3 quarters · filed 2024-04-01 | $18.25M derived: sum of 4 quarters · filed 2024-04-01 |
| 2021-12-31 | $5.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $11.24M derived: sum of 2 quarters · filed 2024-04-01 | $14.36M derived: sum of 3 quarters · filed 2024-04-01 | $17.63M 10-K · filed 2024-04-01 |
| 2021-09-30 | $5.69M 10-Q · filed 2022-11-09 | $8.81M derived: sum of 2 quarters · filed 2022-11-09 | $12.08M 10-Q · filed 2022-11-09 | $15.88M derived: sum of 4 quarters · filed 2023-03-13 |
| 2021-06-30 | $3.12M 10-Q · filed 2022-08-09 | $6.39M 10-Q · filed 2022-08-09 | $10.19M derived: sum of 3 quarters · filed 2023-03-13 | $14.02M derived: sum of 4 quarters · filed 2023-03-13 |
| 2021-03-31 | $3.27M 10-Q · filed 2022-05-10 | $7.07M derived: sum of 2 quarters · filed 2023-03-13 | $10.90M derived: sum of 3 quarters · filed 2023-03-13 | $14.72M derived: sum of 4 quarters · filed 2023-03-13 |
| 2020-12-31 | $3.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $7.63M derived: sum of 2 quarters · filed 2023-03-13 | $11.45M derived: sum of 3 quarters · filed 2023-03-13 | $14.93M 10-K · filed 2023-03-13 |
| 2020-09-30 | $3.82M 10-Q · filed 2021-11-09 | $7.65M derived: sum of 2 quarters · filed 2021-11-09 | $11.12M 10-Q · filed 2021-11-09 | $14.44M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $3.82M 10-Q · filed 2021-08-09 | $7.30M 10-Q · filed 2021-08-09 | $10.62M derived: sum of 3 quarters · filed 2022-03-01 | $14.11M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $3.48M 10-Q · filed 2021-05-10 | $6.79M derived: sum of 2 quarters · filed 2022-03-01 | $10.29M derived: sum of 3 quarters · filed 2022-03-01 | $13.89M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $3.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $6.81M derived: sum of 2 quarters · filed 2022-03-01 | $10.41M derived: sum of 3 quarters · filed 2022-03-01 | $13.79M 10-K · filed 2022-03-01 |
| 2019-09-30 | $3.50M 10-Q · filed 2020-11-09 | $7.09M derived: sum of 2 quarters · filed 2020-11-09 | $10.47M 10-Q · filed 2020-11-09 | $13.29M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $3.60M 10-Q · filed 2020-08-10 | $6.97M 10-Q · filed 2020-08-10 | $9.79M derived: sum of 3 quarters · filed 2021-03-01 | $12.72M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $3.37M 10-Q · filed 2020-05-11 | $6.19M derived: sum of 2 quarters · filed 2021-03-01 | $9.12M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2018-12-31 | $2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $5.75M derived: sum of 2 quarters · filed 2021-03-01 | $11.71M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $2.93M 10-Q · filed 2019-11-12 | $8.90M 10-Q · filed 2019-11-12 | ||
| 2017-12-31 | $12.69M 10-K · filed 2020-03-02 | |||
| 2016-12-31 | $13.58M 10-K · filed 2019-03-01 | |||
| 2015-12-31 | $9.58M 10-K · filed 2018-03-01 | |||
| 2014-12-31 | $8.92M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |